Sector News

Mallinckrodt acquires regenerative medicine company Stratatech

August 19, 2016
Life sciences

Mallinckrodt, a specialty pharma company, announced a merger agreement with Stratatech, a regenerative medicine company. Financial terms were not disclosed, though the acquisition does include worldwide product rights.

Stratatech focuses on proprietary skin substitute products. It’s StrataGraft tech, when approved, will be the first “off-the-shelf” skin substitute that could be used to treat severe burns. Stratatech uses proprietary tissue engineering tech which creates living tissue. That tissue mimics human skin and promotes tissue regeneration.

Autograft–the current standard care for those suffering second- and third-degree burns–is painful and requires harvesting uninjured tissue from an uninjured area. That tissue is grafted to the burned area.

“The [StrataGraft] technology platform provides potential for new products through genetically enhanced tissues, applied topically, that produce elevated levels of natural wound healing and antimicrobial factors,” Mallinckrodt explained in the announcement.

Mark Trudeau, the CEO and president of Mallinckrodt, noted that this acquisition will boost Mallinckrodt’s hosptial growth business.

“The addition of this highly durable, cutting-edge development portfolio and technology platform to our hospital growth business is an excellent example of Mallinckrodt’s Acquire to Invest strategy,” Trudeau said in the announcement. “We believe Stratatech’s technology has the potential to transform the standard of treatment for wound care. Additionally, the acquisition will bring world-class Stratatech researchers with deep expertise in cell-based, differentiated regenerative medicine to Mallinckrodt’s research team.”

StrataGraft is currently an investigational product in Phase III development for the treatment of severe, deep partial thickness burns. It is expected that the FDA will have an approval decision by 2020.

The FDA gave StrataGraft orphan product status in 2012. The product is being developed as a biologic and would be filed under a BLA. This would offer regulatory protection until 2032.

Stratatech is also working under two contracts, one with the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and the Biomedical Advanced Research and Development Authority (BARDA). Mallinckrodt will be required to continue seamless execution of all contractual obligations per the agreement with BARDA. These contracts will help advance development in manufacturing, clinical studies and product procurement with the two agencies.

Stratatech has independent agreements with the U.S. Department of Defense.

By Alyssa Huntley

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach